Literature DB >> 15132209

The global cardiovascular diseases risk pattern in a peri-urban working-class community in South Africa. The Mamre study.

Krisela Steyn1, Naomi S Levitt, Margaret Hoffman, A David Marais, Jean M Fourie, Estelle V Lambert, Thomas A Gaziano, Lulama Kepe, Carl J Lombard.   

Abstract

OBJECTIVES: To describe the cardiovascular disease (CVD) risk factors and the global burden of CVD risk in a peri-urban, working-class community of Mamre near Cape Town. To identify additional variables in the data set associated with the global CVD risk factor score. The latter was calculated using the major CVD risk factors in formulas derived from the Framingham global CVD risk calculations. Such variables could possibly be used for global CVD risk calculations, instead of depending on biochemical estimates for these calculations.
METHODS: In a random population-based sample of 976 people aged 15 years and older, data on demography, smoking, physical activity, and alcohol use were collected. Blood pressure (BP), anthropometry, levels of serum glucose and lipids, and low-density lipoprotein cholesterol (LDL) particle sizes were also determined. These data allowed calculation of the global CVD risk profile with the Framingham study's formula. The data are age-standardized to the colored (mixed ancestry) population according to the 1996 South African census.
RESULTS: The global CVD risk score suggested that men and women had a 5.2% and 4.2% probability, respectively, of having a CVD event in the next 10 years, while for those 55 years of age and older, the probability increased to more than 30% and 25%, respectively. Hypertension was found in 22% of men and 16% of women. Sixty-two percent of the men and 44% of the women smoked cigarettes, while 6% and 5% had diabetes, respectively. Hypercholesterolemia was present in 47% of men, and 46% of women. Small-dense LDL particles were present in 26% of men and 14% of women. A number of easily measured CVD risk factors could explain 40.3% of the variation of the global CVD risk score. These include aspects of the medical history provided by the patient, the inverse of the amount of physical activity and weight measurements, as well as height, and waist circumference.
CONCLUSIONS: The people in Mamre have a high probability of suffering a CVD event in the next 10 years. Age and gender are the primary contributors to the global CVD risk score. The findings suggest the possibility of developing a global CVD risk score based on easily measured CVD risk factors for use in developing countries with limited resources.

Entities:  

Mesh:

Year:  2004        PMID: 15132209

Source DB:  PubMed          Journal:  Ethn Dis        ISSN: 1049-510X            Impact factor:   1.847


  10 in total

1.  Elevated hypertension risk for African-origin populations in biracial societies: modeling the Epidemiologic Transition Study.

Authors:  Richard S Cooper; Terrence E Forrester; Jacob Plange-Rhule; Pascal Bovet; Estelle V Lambert; Lara R Dugas; Kathryn E Cargill; Ramon A Durazo-Arvizu; David A Shoham; Liping Tong; Guichan Cao; Amy Luke
Journal:  J Hypertens       Date:  2015-03       Impact factor: 4.844

Review 2.  Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.

Authors:  Thomas A Gaziano; Lionel H Opie; Milton C Weinstein
Journal:  Lancet       Date:  2006-08-19       Impact factor: 79.321

3.  Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study.

Authors:  M Aboud; A Elgalib; L Pomeroy; G Panayiotakopoulos; E Skopelitis; R Kulasegaram; C Dimian; F C Lampe; A Duncan; A S Wierzbicki; B S Peters
Journal:  Int J Clin Pract       Date:  2010-08       Impact factor: 2.503

4.  HealthKick: a nutrition and physical activity intervention for primary schools in low-income settings.

Authors:  Catherine E Draper; Anniza de Villiers; Estelle V Lambert; Jean Fourie; Jillian Hill; Lucinda Dalais; Zulfa Abrahams; Nelia P Steyn
Journal:  BMC Public Health       Date:  2010-07-06       Impact factor: 3.295

5.  Comparative assessment of absolute cardiovascular disease risk characterization from non-laboratory-based risk assessment in South African populations.

Authors:  Thomas A Gaziano; Ankur Pandya; Krisela Steyn; Naomi Levitt; Willie Mollentze; Gina Joubert; Corinna M Walsh; Ayesha A Motala; Annamarie Kruger; Aletta E Schutte; Datshana P Naidoo; Dorcas R Prakaschandra; Ria Laubscher
Journal:  BMC Med       Date:  2013-07-24       Impact factor: 8.775

6.  The 30-year cardiovascular risk profile of South Africans with diagnosed diabetes, undiagnosed diabetes, pre-diabetes or normoglycaemia: the Bellville, South Africa pilot study.

Authors:  T E Matsha; M S Hassan; M Kidd; R T Erasmus
Journal:  Cardiovasc J Afr       Date:  2012-02       Impact factor: 1.167

7.  Distribution and association of hs-CRP with cardiovascular risk variables of metabolic syndrome in adolescent learners.

Authors:  Megan A Rensburg; Tandi Matsha; Mariza Hoffmann; Mogamat S Hassan; Rajiv T Erasmus
Journal:  Afr J Lab Med       Date:  2012-06-04

8.  Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study.

Authors:  Omar Hamoui; Mohamed I Omar; Frederick J Raal; Wafa Rashed; Abdoul Kane; Mohamed Alami; Paula Abreu; Walid Mashhoud; Alawi A Alsheikh-Ali
Journal:  BMC Cardiovasc Disord       Date:  2019-03-15       Impact factor: 2.298

9.  Estimating the prevalence and awareness rates of hypertension in Africa: a systematic analysis.

Authors:  Davies Adeloye; Catriona Basquill
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

10.  Application of the modified Framingham cardiovascular risk score to newly diagnosed type 2 black African diabetic patients.

Authors:  Andre Pascal Kengne; Mesmin Dehayem; Simeon Pierre Choukem; Paschal Awah; Jean-Claude Mbanya
Journal:  Cardiovasc J Afr       Date:  2007 Jul-Aug       Impact factor: 1.167

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.